Comparative Pharmacology
Head-to-head clinical analysis: DEXONE 4 versus METICORTEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXONE 4 versus METICORTEN.
DEXONE 4 vs METICORTEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a long-acting glucocorticoid receptor agonist, binding to glucocorticoid response elements to modulate gene transcription, resulting in anti-inflammatory, immunosuppressive, anti-allergic, and anti-shock effects.
Prednisone is a prodrug that is converted to prednisolone, which binds to the glucocorticoid receptor, modulating gene expression and suppressing inflammation, immune response, and adrenal function.
Oral: 0.75–9 mg/day divided every 6–12 hours; IV/IM: 0.5–9 mg/day divided every 6–12 hours.
5-60 mg orally once daily, depending on condition; for acute exacerbations, up to 250 mg IV every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life: 2-3 hours (oral); clinical effects persist longer due to glucocorticoid receptor-mediated genomic actions
Following oral or IV administration, the terminal elimination half-life of total prednisolone (active form) is 2.1–3.5 hours in adults with normal hepatic function. In hepatic impairment, half-life may be prolonged (up to 6–8 hours), necessitating dose adjustment.
Renal excretion of metabolites (<5% unchanged drug); minor biliary/fecal elimination (<1%)
Primarily renal: approximately 80% as inactive metabolites (conjugated and oxidized forms) and <5% as unchanged prednisolone. Biliary/fecal excretion accounts for about 10-15% of the dose.
Category C
Category C
Corticosteroid
Corticosteroid